A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in

See also
Status	Clinical Trial	Phase
Completed	`NCT00069862` - Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia	Phase 1/Phase 2
Completed	`NCT00733811` - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP	Phase 4
Completed	`NCT05506358` - Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada	N/A
Withdrawn	`NCT04938635` - Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Completed	`NCT06239389` - Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.	Phase 2
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT03271541` - A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia	Phase 2
Terminated	`NCT02274233` - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia	Phase 1
Completed	`NCT01206075` - Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major	N/A
Recruiting	`NCT05567458` - A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT03961828` - Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus	Phase 4
Recruiting	`NCT06065189` - Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major	Early Phase 1
Recruiting	`NCT04143724` - Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia	Phase 2
Not yet recruiting	`NCT01996683` - Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)	N/A
Completed	`NCT02268409` - ACE-536 Extension Study - Beta Thalassemia	Phase 2
Active, not recruiting	`NCT01016093` - Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients	Phase 2/Phase 3
Completed	`NCT01039636` - Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload	Phase 1
Withdrawn	`NCT01927913` - Treatment of Iron Overload Requiring Chelation Therapy	Phase 2

NCT number	NCT03381833
Study type	Interventional
Source	La Jolla Pharmaceutical Company
Contact
Status	Terminated
Phase	Phase 2
Start date	November 30, 2017
Completion date	January 14, 2020

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms